K Reich

Summary

Affiliation: Dermatologikum Hamburg
Country: Germany

Publications

  1. pmc Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)
    Ina Zschocke
    SCIderm GmbH, Drehbahn 1 3, 20354, Hamburg, Germany
    Arch Dermatol Res 306:287-97. 2014
  2. doi request reprint The concept of psoriasis as a systemic inflammation: implications for disease management
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 26:3-11. 2012
  3. ncbi request reprint An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up
    Kristian Reich
    Dermatologikum Hamburg, Germany
    J Drugs Dermatol 11:300-12. 2012
  4. doi request reprint What is new in topical therapy for psoriasis?
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 25:15-20. 2011
  5. doi request reprint Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Am Acad Dermatol 63:1011-8. 2010
  6. doi request reprint Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Dermatology 221:172-8. 2010
  7. ncbi request reprint Treatment goals in psoriasis
    Kristian Reich
    Dermatologikum Hamburg, Germany
    J Dtsch Dermatol Ges 5:566-74. 2007
  8. ncbi request reprint Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Curr Med Res Opin 24:1237-54. 2008
  9. doi request reprint Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE)
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Dtsch Dermatol Ges 7:603-11. 2009
  10. doi request reprint Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus
    Kristian Reich
    Department of Dermatology, Dermatologikum Hamburg, Hamburg, Germany
    Dermatology 217:268-75. 2008

Detail Information

Publications68

  1. pmc Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)
    Ina Zschocke
    SCIderm GmbH, Drehbahn 1 3, 20354, Hamburg, Germany
    Arch Dermatol Res 306:287-97. 2014
    ....
  2. doi request reprint The concept of psoriasis as a systemic inflammation: implications for disease management
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 26:3-11. 2012
    ..Such an approach has the potential to significantly improve patient outcomes through the treatment of psoriasis itself and possibly also in protection against co-morbidities...
  3. ncbi request reprint An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up
    Kristian Reich
    Dermatologikum Hamburg, Germany
    J Drugs Dermatol 11:300-12. 2012
    ..The efficacy and safety profile of ustekinumab with up to three years of exposure suggested a favorable benefit-risk profile in patients with moderate to severe psoriasis...
  4. doi request reprint What is new in topical therapy for psoriasis?
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 25:15-20. 2011
    ..The availability of this new gel thus increases patient choice. Ultimately, treatment should always be tailored to match individual patients' needs...
  5. doi request reprint Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Am Acad Dermatol 63:1011-8. 2010
    ..The Comparative Study of Humira versus Methotrexate (MTX) versus Placebo in Psoriasis Patients (CHAMPION) demonstrated superior efficacy of biologic over conventional systemic immunosuppressant therapy in psoriasis...
  6. doi request reprint Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Dermatology 221:172-8. 2010
    ..The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails...
  7. ncbi request reprint Treatment goals in psoriasis
    Kristian Reich
    Dermatologikum Hamburg, Germany
    J Dtsch Dermatol Ges 5:566-74. 2007
    ..Patients should carefully be monitored for the presence of psoriatic arthritis and comorbidities because these may need to be integrated in the planning of treatment goals on an interdisciplinary basis...
  8. ncbi request reprint Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Curr Med Res Opin 24:1237-54. 2008
    ..The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated...
  9. doi request reprint Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE)
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Dtsch Dermatol Ges 7:603-11. 2009
    ..This study collected data on the safety and efficacy of fumaric acid esters (FAE; Fumaderm) in the long-term treatment of psoriasis...
  10. doi request reprint Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus
    Kristian Reich
    Department of Dermatology, Dermatologikum Hamburg, Hamburg, Germany
    Dermatology 217:268-75. 2008
    ..To date, there is little or no information about the long-term management in clinical trials or guidelines...
  11. doi request reprint The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab
    Kristian Reich
    Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany
    Arch Dermatol Res 300:537-44. 2008
    ..There is also evidence, that large improvements of HRQoL as currently discussed as treatment goals in psoriasis are primarily achieved in patients with an at least 75% reduction of their PASI...
  12. doi request reprint Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis
    K Reich
    Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany
    Br J Dermatol 160:1040-7. 2009
    ..Because psoriatic arthritis (PsA) usually develops years after the first manifestation of skin symptoms, in many cases the initial diagnosis of PsA depends on the dermatologist...
  13. doi request reprint Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data
    R M Szeimies
    Department of Dermatology, Regensburg University Hospital, Franz Josef Strauss Allee 11, Regensburg, Germany
    Br J Dermatol 162:410-4. 2010
    ..Photodynamic therapy with a self-adhesive 5-aminolaevulinic acid (5-ALA) patch shows high efficacy rates in the treatment of mild to moderate actinic keratosis (AK) in short term trials...
  14. ncbi request reprint Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis
    K Reich
    Department of Dermatology, Georg August University Gottingen, Germany
    J Invest Dermatol 113:214-20. 1999
    ..Our results suggest that male carriers of the G-->A polymorphism at position -238 of the tumor necrosis factor-alpha promoter are at an increased risk to develop early-onset psoriasis...
  15. ncbi request reprint Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation
    K Reich
    Department of Dermatology, Georg August University, von Siebold Strasse 3, 37075 Gottingen, Germany
    J Invest Dermatol 116:319-29. 2001
    ..Genotypic analysis may help to identify patients that will preferentially respond to interleukin-10 therapy...
  16. ncbi request reprint Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology
    V Blaschke
    Department of Dermatology, von Siebold Str 3, D 37075, Goettingen, Germany
    J Immunol Methods 246:79-90. 2000
    ..In summary, real-time RT-PCR is a sensitive and rapid tool for quantifying mRNA expression even with small quantities of tissue. The results obtained do not differ from those generated by quantitative competitive RT-PCR...
  17. ncbi request reprint Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus
    K Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    Br J Dermatol 141:739-46. 1999
    ..Our findings support the concept of a major contribution of cytotoxic T lymphocytes to the immunopathology of paraneoplastic pemphigus...
  18. doi request reprint Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany
    M Augustin
    Health Economics and Quality of Life Research Group, Department of Dermatology, University Clinics of Hamburg, Hamburg, Germany
    Dermatology 216:366-72. 2008
    ..Plaque-type psoriasis produces significant morbidity, has negative effects on patients' health-related quality of life (HRQoL), and represents an economic burden...
  19. doi request reprint An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals
    U Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Br J Dermatol 168:374-80. 2013
    ..The European Consensus Programme (ECP) established pan-European consensus definitions of psoriasis disease severity and treatment goals among 19 psoriasis experts from European nations...
  20. doi request reprint Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany Dalhousie University, Halifax, NS, Canada
    Br J Dermatol 164:862-72. 2011
    ..Patients with psoriasis are believed to be at an increased risk of cardiovascular (CV) morbidity, and the effect of biological agents on CV safety is not fully understood...
  21. doi request reprint Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators
    M A Radtke
    German Center for Health Services Research in Dermatology CVderm, Department of Dermatology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Dermatology 219:54-8. 2009
    ..To date, no standardised indicators for quality of care in psoriasis have been published...
  22. ncbi request reprint Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
    K Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    Br J Dermatol 154:1161-8. 2006
    ..Psoriasis has a well-documented, markedly negative effect on patient quality of life...
  23. ncbi request reprint Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis
    Kristian Reich
    Department of Dermatology, Georg August University Von SieboldStrasse 3, 37075, Gottingen, Germany
    Eur J Dermatol 17:381-6. 2007
    ..In placebo patients who crossed over to infliximab, these scores improved and approached those seen with infliximab at week 50. Infliximab significantly improved productivity and ability to work in psoriasis patients...
  24. doi request reprint Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey
    M A Radtke
    German Center for Health Services Research in Dermatology, Health Economics and QoL Research Group, Department of Dermatology, University Clinics of Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 23:683-91. 2009
    ..Evidence that affected patients can have significant radiographic joint damage, functional impairment, reduced quality of life and long-term work disability is increasing...
  25. ncbi request reprint Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides
    V Blaschke
    Department of Dermatology, Georg August University, Gottingen, Germany
    J Invest Dermatol 113:658-63. 1999
    ....
  26. doi request reprint Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting
    U Mrowietz
    Department of Dermatology, Psoriasis Center, University Medical Center Schleswig Holstein, Kiel, Germany
    J Eur Acad Dermatol Venereol 25:1-13. 2011
    ..5 day educational meeting run by the Progressive Psoriasis Initiative to discuss how treatment goals in psoriasis might best be implemented in clinical practice. The meeting conclusions are presented here...
  27. doi request reprint Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab
    Rotraut Mossner
    Department of Dermatology, Georg August University, Gottingen, Germany
    Curr Probl Dermatol 38:107-36. 2009
    ..In this chapter, we give an introduction to the different TNF antagonists, with the main focus on therapy management and safety issues...
  28. doi request reprint Epidemiology and comorbidity of psoriasis in children
    M Augustin
    CVderm German Center for Health Services Research in Dermatology, Department of Dermatology, University Clinics of Hamburg, Hamburg, Germany
    Br J Dermatol 162:633-6. 2010
    ..Psoriasis is a common disease affecting all age groups. In contrast to adult psoriasis, only few studies on the epidemiology of childhood psoriasis have been published...
  29. ncbi request reprint Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study
    R M Szeimies
    Department of Dermatology, Regensburg University Hospital, Regensburg, Germany
    Br J Dermatol 163:386-94. 2010
    ..Different strategies are applied to overcome the chemical instability of ALA in solution and to improve skin penetration. A new stable nanoemulsion-based ALA formulation, BF-200 ALA, is currently in clinical development for PDT of AK...
  30. ncbi request reprint Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
    Kristian Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    Lancet 366:1367-74. 2005
    ..We assessed the efficacy and safety of continuous treatment with infliximab, a monoclonal antibody that binds to and neutralises the activity of TNFalpha, in patients with psoriasis...
  31. doi request reprint Tumor necrosis factor antagonists in the therapy of psoriasis
    Rotraut Mossner
    Department of Dermatology, Georg August University, von Siebold Str 3, 37075 Gottingen, Germany
    Clin Dermatol 26:486-502. 2008
    ..This article may be helpful for the daily routine when selecting the right therapy for a patient and managing the TNF antagonist during maintenance therapy...
  32. doi request reprint A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
    U Mrowietz
    Department of Dermatology, Psoriasis Center, University Medical Center, Schleswig Holstein Campus Kiel, Kiel, Germany
    J Eur Acad Dermatol Venereol 28:438-53. 2014
    ..There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice...
  33. doi request reprint Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)
    K Reich
    Dermatologikum Hamburg, Drehbahn 1 3 20354, Hamburg, Germany
    Br J Dermatol 168:1325-34. 2013
    ..Continuous maintenance therapy with infliximab 5 mg kg(-1) every 8 weeks is effective for moderate-to-severe plaque-type psoriasis...
  34. doi request reprint [Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy]
    C Kahl
    Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Deutschland
    Hautarzt 63:184-91. 2012
    ..There is limited evidence for the efficacy of topical therapies in nail psoriasis. A number of large studies document an improvement of nail psoriasis in response to biologics and, more recently, also to methotrexate...
  35. doi request reprint Approach to managing patients with nail psoriasis
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany
    J Eur Acad Dermatol Venereol 23:15-21. 2009
    ..Infliximab has been shown to improve psoriatic nail lesions and quality of life, and it should be considered as one of the most appropriate available treatment options for the many patients with this distressing condition...
  36. ncbi request reprint Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis
    Kristian Reich
    Dermatologikum, Hamburg, Germany
    Dermatology 219:239-49. 2009
    ..To assess baseline patient-reported outcomes (PROs) and PRO improvement in patients with psoriasis administered etanercept 50 mg once weekly (QW)...
  37. pmc Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
    Rotraut Mossner
    Department of Dermatology, Georg August University, Gottingen, Germany
    Arch Dermatol Res 300:101-5. 2008
    ..Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role...
  38. ncbi request reprint Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial
    C Muller
    Department of Medical Science and Operations, RIEMSER Arzneimittel AG, Greifswald, Germany Department of Dermatology, Venereology, and Allergology, University Hospital Wurzburg, Wurzburg, Germany Private Dermatological Practice Centre, Wuppertal, Germany SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany Skin and Laser Center Potsdam, Potsdam, Germany Division of Evidence Based Medicine, Klinik fur Dermatologie, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Eur Acad Dermatol Venereol 27:1278-84. 2013
    ..Focal hyperhidrosis can severely affect quality of life. So far, knowledge on the effect of systemic therapy of focal hyperhidrosis is limited...
  39. pmc Definition of treatment goals for moderate to severe psoriasis: a European consensus
    U Mrowietz
    Department of Dermatology, University Medical Center Schleswig Holstein, Kiel, Germany
    Arch Dermatol Res 303:1-10. 2011
    ..It is planned to evaluate the implementation of these treatment goals in a subsequent programme involving patients and physicians...
  40. doi request reprint Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
    K Reich
    Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany
    Br J Dermatol 167:180-90. 2012
    ..Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent...
  41. doi request reprint Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials
    K Reich
    Dermatologikum Hamburg, Drehbahn 1 3, 20354 Hamburg, Germany
    Br J Dermatol 166:179-88. 2012
    ..These estimates have previously been published for a limited range of psoriasis biologic treatments, although, to date no review has compared all the currently available agents in Europe...
  42. doi request reprint Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes
    M Augustin
    University Medical Center Hamburg Eppendorf, Institute for Health Services Research in Dermatology and Nursing, Hamburg, Germany
    Br J Dermatol 170:591-8. 2014
    ..Existing tools for nail psoriasis are complex and may not adequately measure outcomes that are important to patients...
  43. ncbi request reprint Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation
    R Mossner
    Department of Dermatology, Georg August University Gottingen, Germany
    Exp Dermatol 13:340-6. 2004
    ....
  44. ncbi request reprint Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?
    J M Schroder
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, University of Kiel, D 24105 Kiel, Germany
    Exp Dermatol 15:913-29. 2006
    ..By the time the curtain drops, you will have reached your own, independent conclusions on how to answer the title question of this play - at least for the time being.....
  45. doi request reprint Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies
    A Hauschild
    Department of Dermatology, Venereology and Allergology, University of Kiel, Schittenhelmstr 7, D 24105 Kiel, Germany
    Br J Dermatol 160:1066-74. 2009
    ..Photodynamic therapy (PDT) is increasingly used for treatment of actinic keratoses (AKs) but is a cumbersome procedure. A thin self-adhesive patch (PD P 506 A) containing 5-aminolaevulinic acid (5-ALA) was developed to facilitate PDT...
  46. ncbi request reprint Use of fumaric acid esters in psoriasis
    Antonie Roll
    Department of Dermatology, Dermatologikum, Hamburg, Germany
    Indian J Dermatol Venereol Leprol 73:133-7. 2007
    ..Tolerance is limited by gastrointestinal side effects and flushing of the skin. This article reviews pharmacokinetics, uses, contraindications, dosages and side effects of treatment with FAEs...
  47. ncbi request reprint Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial
    Ina Zschocke
    SCIderm Institute for Clinical Research, Hamburg, Germany
    J Dermatolog Treat 19:176-81. 2008
    ..To compare silica gel with acyclovir cream in the treatment of recurrent herpes labialis...
  48. doi request reprint [Paradoxical skin reactions under therapy with TNF-alpha antagonists]
    P Weisenseel
    Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Deutschland
    Z Rheumatol 72:423-8. 2013
    ..This article provides an overview of the different variants of paradoxical skin reactions due to TNF α inhibitors and gives practical advice on the therapeutic consequences...
  49. doi request reprint One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis
    K Reich
    Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Germany Georg August University, Gottingen, Germany
    Br J Dermatol 170:435-44. 2014
    ..There are limited long-term, 'real-world' data on ustekinumab, or the effect of dose adjustment in suboptimal responders...
  50. ncbi request reprint Non-adherence and measures to improve adherence in the topical treatment of psoriasis
    I Zschocke
    SCIderm GmbH, Hamburg, Germany
    J Eur Acad Dermatol Venereol 28:4-9. 2014
    ..Such an individualized and comprehensive adherence-enhancing intervention would probably enable the successful long-term management of this disabling chronic condition. ..
  51. doi request reprint Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors
    C Sunderkotter
    Department of Dermatology, University of Munster, Von Esmarch Str 58, 48149 Munster, Germany
    Br J Dermatol 160:835-43. 2009
    ..For optimal management it would be useful to identify the risk factors for DU. Such statistical analyses have been rare because they require a high number of patients...
  52. ncbi request reprint Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset
    Kristian Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    J Invest Dermatol 118:155-63. 2002
    ..They also provide further evidence that patients with early and late onset psoriasis differ in their genetic background...
  53. pmc Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris
    Rotraut Mossner
    Department of Dermatology, Georg August University, von Siebold Strasse 3, Gottingen 37075, Germany
    Arch Dermatol Res 301:443-7. 2009
    ..These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients...
  54. ncbi request reprint Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis
    Kristian Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    J Allergy Clin Immunol 109:681-7. 2002
    ..Recently, epidermal cells in lesional AD were reported to contain increased messenger (m)RNA levels of IL-16, a cytokine that induces chemotactic responses in CD4(+)T cells, monocytes, and eosinophils...
  55. ncbi request reprint How do regional factors influence psoriasis patient care in Germany?
    Marc Alexander Radtke
    CVderm Competence Center for Healthcare Research in Dermatology, University Hospital, Hamburg Eppendorf, Hamburg, Germany
    J Dtsch Dermatol Ges 8:516-24. 2010
    ..It remained unclear whether regional differences in psoriasis health care have an influence on patient outcomes in Germany...
  56. ncbi request reprint Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk
    Rotraut Mossner
    Department of Dermatology, Georg August University, von Siebold Strasse 3, D 37075 Gottingen, Germany
    Cancer Lett 246:218-23. 2007
    ..We therefore conclude that the investigated PPARG polymorphisms are not likely to constitute a significant risk factor for the development of melanoma among German Caucasians...
  57. ncbi request reprint Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study
    Sandra Blankenburg
    Department of Dermatology, Georg August University, Goettingen, Germany
    Carcinogenesis 26:1085-90. 2005
    ..Our results should be validated in independent samples in order to guard against false positive findings...
  58. ncbi request reprint The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta
    Kristian Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    Exp Dermatol 13:740-7. 2004
    ..There is evidence that DC-derived IL-16 may contribute to the pathogenesis of atopic dermatitis (AD)...
  59. ncbi request reprint Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis
    Rotraut Mossner
    Department of Dermatology, Georg August University, von Siebold Strasse 3, 37075 Goettingen, Germany
    Arch Dermatol Res 296:1-5. 2004
    ..No association between any of the investigated PPAR variants and psoriasis was found. Our findings argue against a significant contribution of the investigated PPAR variations to the genetic basis of psoriasis...
  60. doi request reprint Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    Kim A Papp
    Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
    Lancet 371:1675-84. 2008
    ..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders...
  61. ncbi request reprint Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris
    Alexander Nast
    Division of Evidence Based Medicine dEBM, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Germany
    J Dtsch Dermatol Ges 5:1-119. 2007
    ..The therapeutic recommendations were developed by an expert group and finalized during interdisciplinary consensus conferences...
  62. ncbi request reprint Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study
    Oliver Schöffski
    University of Erlangen Nuremberg, Germany
    J Dtsch Dermatol Ges 5:209-18. 2007
    ..This study evaluated costs, disease severity and health-related quality of life (QoL) in patients with moderate to severe plaque-type psoriasis...
  63. ncbi request reprint [S3-Guidelines for the therapy of psoriasis vulgaris]
    Alexander Nast
    Division of Evidence Based Medicine dEBM, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin
    J Dtsch Dermatol Ges 4:S1-126. 2006
  64. ncbi request reprint [Therapy of psoriasis vulgaris with efalizumab]
    Ulrich Mrowietz
    Universitäts Hauklinik Kiel
    J Dtsch Dermatol Ges 4:511-2. 2006
  65. ncbi request reprint Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris
    Rotraut Mossner
    J Invest Dermatol 124:282-4. 2005
  66. ncbi request reprint Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)
    Andrea Niedermeier
    Klinik für Dermatologie und Allergologie, Universitätsklinikum Giessen und Marburg, Philipps Universitat, Marburg, Germany
    Arch Dermatol 143:192-8. 2007
    ..We describe herein the therapeutic response of 2 patients with recalcitrant mechanobullous EBA to combined treatment with immunoadsorption and rituximab, an anti-CD20 monoclonal antibody that induces depletion of B cells in vivo...
  67. ncbi request reprint Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
    Phoebe Rich
    Oregon Health Sciences University, Dermatology and Clinical Research, Portland, Oregon 97210, USA
    J Am Acad Dermatol 58:224-31. 2008
    ..Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited...
  68. ncbi request reprint [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]
    Ulrich Mrowietz
    Universitäts Hauklinik Kiel, D 24105 Kiel
    J Dtsch Dermatol Ges 4:444-7. 2006